Dengue remains a major public health challenge in India. Data from the Integrated Health Information Platform (IHIP) ...

India's one-shot dengue vaccine 'DengiAll' reaches 70% enrolment in Phase III trials across 20 national sites.

A large-scale analysis of health records reveals that subtle signs of multiple sclerosis (MS) may appear more than a decade ...

The earliest warning signs of multiple sclerosis (MS) may emerge more than a decade before the first classical neurological ...

Identifying type 1 diabetes before stage 1 and developing more tailored therapies through a better understanding of the ...

Ocugen has scheduled a conference call and webcast for 8:30 a.m. ET today to discuss the financial results and recent business highlights. Ocugen’s executive leadership team will host the call, which ...

Updated cash guidance provides runway into at least the middle of calendar 2026 Company remains encouraged by MDNA11 clinical results presented to-date, demonstrating best-in-class potential of our IL ...

(NASDAQ:MRNA) today reported financial results and provided business updates for the second quarter of 2025. "In the last three months, we advanced our pipeline with positive Phase 3 flu vaccine ...

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development ...

Seventy per cent enrolment of participants for the Phase III clinical trial of the indigenous one-shot dengue vaccine, DengiAll, has been completed, Minister of State for Health, Prataprao Jadhav, ...

A two-drug combination for treating advanced kidney cancer has shown sustained and durable clinical benefit in more than five ...